Senseonics to Participate in the Guggenheim MedTech Disruptors Summit

Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in the upcoming Guggenheim MedTech Disruptors Summit in New York, NY.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, May 21, 2019
Information
Tags: 
Health, Medical devices, Diabetes, Managed care, Medicine, Medical technology, Blood tests, Medical monitoring, Continuous glucose monitor, Clinical medicine, Blood glucose monitoring, Zimmer Biomet Robotics, Medtech, CGM, Diabetes
Geotags: 
United States, MARYLAND, NEW YORK
⚠generated by AI ↴
Summary
Key Points: 
  • Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the company plans to participate in the upcoming Guggenheim MedTech Disruptors Summit in New York, NY.
  • Interested parties may access a live and recorded webcast of the presentation on the Investor Relations section of the companys website at www.senseonics.com .
  • From its inception, Senseonics has been advancing the integration of novel, fluorescence sensor technology with smart wearable devices.
  • The Eversense XL CGM System received CE mark for up to 180 days of continuous use and is available in Europe.


Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology
company focused on the development and commercialization of a long-term,
implantable continuous glucose monitoring (CGM) system for people with
diabetes, today announced the company plans to participate in the
upcoming Guggenheim MedTech Disruptors Summit in New York, NY.

Management is scheduled to present Wednesday, May 29, 2019 at 10:00am
ET. Interested parties may access a live and recorded webcast of the
presentation on the “Investor Relations” section of the company’s
website at www.senseonics.com.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of transformative glucose
monitoring products designed to help people with diabetes confidently
live their lives with ease. From its inception, Senseonics has been
advancing the integration of novel, fluorescence sensor technology with
smart wearable devices. The Eversense® CGM System received
PMA approval from the FDA for up to 90 days of continuous use and is
available in the United States. The Eversense® XL CGM System
received CE mark for up to 180 days of continuous use and is available
in Europe. For more information on Senseonics, please visit www.senseonics.com.

Copyright: 
Copyright Business Wire 2019